Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation
Pierre Bohanes(University of Southern California), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Cornelia M. Ulrich(University of Utah), Al B. Benson(Northwestern University), Charles D. Blanke(SWOG Cancer Research Network), James A. Martensen(Toyota Motor Corporation (Switzerland)), Robert J. Mayer(Applied Natural Sciences), Thomas Winder, Kathleen D. Danenberg(University of Southern California), Stephen R. Smalley(Mayo Clinic), C. Cripps(Canadian Partnership Against Cancer), Jacqueline Benedetti(University of Illinois Chicago), Tyvin A. Rich(The University of Texas MD Anderson Cancer Center), Cathryn Rankin(Cleveland Clinic), Wu Zhang, Karen W. Makar(Fred Hutch Cancer Center)
Cited by 11
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k